Cipla liquidates wholly-owned unit as part of internal reorganisation

Topics Cipla

Illustration: Ajay Mohanty

Drug major Cipla on Saturday said it has voluntarily liquidated a wholly-owned step-down subsidiary.

This liquidation was a part of internal reorganisation and it will not affect performance or revenue of the company, Cipla said in a BSE filing.

"Cipla (UK) Ltd, a wholly owned subsidiary of Cipla (EU) Ltd and a wholly -owned step down subsidiary of the company, has been voluntarily liquidated with effect from March 5, 2021," the Mumbai-based drug firm said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel